Report for: Intravenous immunoglobulin for myasthenia gravis

Title	Intravenous immunoglobulin for myasthenia gravis
Published in	Cochrane database of systematic reviews, December 2012
DOI	10.1002/14651858.cd002277.pub4
Pubmed ID	23235588
Authors	Philippe Gajdos, Sylvie Chevret, Klaus V Toyka
Abstract	Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
United States	1	50%
Unknown	1	50%

Demographic breakdown

Type	Count	As %
Members of the public	2	100%

Mendeley readers

The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Spain	2	<1%
Colombia	1	<1%
Brazil	1	<1%
Unknown	211	98%

Demographic breakdown

Readers by professional status	Count	As %
Other	26	12%
Student > Bachelor	23	11%
Student > Master	22	10%
Researcher	20	9%
Student > Doctoral Student	18	8%
Other	55	26%
Unknown	51	24%

Readers by discipline	Count	As %
Medicine and Dentistry	100	47%
Nursing and Health Professions	14	7%
Agricultural and Biological Sciences	9	4%
Pharmacology, Toxicology and Pharmaceutical Science	9	4%
Neuroscience	6	3%
Other	23	11%
Unknown	54	25%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2021.

All research outputs

#4,208,412

of 22,953,506 outputs

Outputs from Cochrane database of systematic reviews

#6,674

of 12,333 outputs

Outputs of similar age

#43,647

of 279,978 outputs

Outputs of similar age from Cochrane database of systematic reviews

#93

of 192 outputs

Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 12,333 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.6. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.

We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.

Cochrane Database of Systematic Reviews

Intravenous immunoglobulin for myasthenia gravis

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context